See the DrugPatentWatch profile for eliquis

The Eliquis Patent Life: Understanding the Expiration Timeline

The pharmaceutical industry is constantly evolving, with new medications emerging and existing ones facing patent expirations. One such medication is Eliquis, a blood thinner developed by Pfizer and Bristol-Myers Squibb. In this article, we will delve into the Eliquis patent life, exploring the expiration timeline and its implications for the pharmaceutical market.

What is Eliquis?

Eliquis, also known as apixaban, is an oral anticoagulant used to prevent and treat blood clots. It works by inhibiting the activity of certain enzymes in the blood, thereby reducing the risk of stroke and other cardiovascular events. Eliquis was approved by the FDA in 2012 and has since become a leading treatment for atrial fibrillation and deep vein thrombosis.

The Eliquis Patent Life

The Eliquis patent life is a critical factor in determining the medication's market exclusivity. According to DrugPatentWatch.com, the original Eliquis patent (US Patent 8,410,329) was filed in 2009 and expired in 2027. However, the patent life is not a straightforward concept, as it involves multiple patents with varying expiration dates.

Patent Expiration Timeline

Here is a breakdown of the Eliquis patent expiration timeline:

* Original Patent (US Patent 8,410,329): Expired on January 17, 2027
* Method of Use Patent (US Patent 9,434,993): Expires on November 7, 2028
* Formulation Patent (US Patent 9,434,994): Expires on November 7, 2028
* Generic Patent (US Patent 10,439,111): Expires on June 17, 2030

Implications of Patent Expiration

The expiration of the Eliquis patent has significant implications for the pharmaceutical market. As the patent expires, generic versions of the medication will become available, increasing competition and potentially driving down prices. This, in turn, may lead to increased market share for generic versions of Eliquis.

Impact on Pfizer and Bristol-Myers Squibb

The expiration of the Eliquis patent will also impact Pfizer and Bristol-Myers Squibb, the manufacturers of the medication. As the patent expires, the companies will no longer have exclusive rights to the medication, and generic versions will become available. This may lead to a decline in sales and revenue for the companies.

Generic Versions of Eliquis

Several generic versions of Eliquis are already in development, with companies such as Mylan, Teva, and Sandoz seeking FDA approval. These generic versions will be manufactured using the same active ingredient as Eliquis, but at a lower cost.

Expert Insights

According to a report by EvaluatePharma, the generic version of Eliquis is expected to capture 70% of the market share by 2025. This is a significant increase from the current market share of 20% held by generic versions of other anticoagulants.

Conclusion

The Eliquis patent life is a complex and multifaceted concept, involving multiple patents with varying expiration dates. As the patent expires, generic versions of the medication will become available, increasing competition and potentially driving down prices. This will have significant implications for the pharmaceutical market, as well as for Pfizer and Bristol-Myers Squibb, the manufacturers of Eliquis.

Key Takeaways

* The original Eliquis patent (US Patent 8,410,329) expired on January 17, 2027.
* Multiple patents with varying expiration dates are associated with Eliquis.
* Generic versions of Eliquis are already in development and expected to capture 70% of the market share by 2025.
* The expiration of the Eliquis patent will have significant implications for the pharmaceutical market and for Pfizer and Bristol-Myers Squibb.

Frequently Asked Questions

1. Q: What is the current market share of generic versions of Eliquis?
A: The current market share of generic versions of Eliquis is 20%.
2. Q: How much of the market share is expected to be captured by generic versions of Eliquis by 2025?
A: Generic versions of Eliquis are expected to capture 70% of the market share by 2025.
3. Q: What is the expiration date of the original Eliquis patent?
A: The original Eliquis patent (US Patent 8,410,329) expired on January 17, 2027.
4. Q: What are the implications of the Eliquis patent expiration for Pfizer and Bristol-Myers Squibb?
A: The expiration of the Eliquis patent will lead to a decline in sales and revenue for Pfizer and Bristol-Myers Squibb.
5. Q: What is the expected impact of generic versions of Eliquis on the pharmaceutical market?
A: Generic versions of Eliquis are expected to increase competition and potentially drive down prices in the pharmaceutical market.

Sources:

1. DrugPatentWatch.com
2. EvaluatePharma
3. Pfizer
4. Bristol-Myers Squibb
5. FDA

Note: The information provided in this article is based on publicly available data and may not reflect the current market situation.